Stock listing
NASDAQ:BLSM BlossomHill Therapeutics, Inc. Stock
Home listing (NASDAQ) of BlossomHill Therapeutics, Inc.
Follow BlossomHill Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:BLSM
$14.51 USD -0.08 (-0.5%)
Close on Nov 20, 2026
- Day range
- $13.90 – $15.63 USDNov 20, 2026
- Volume
- 270,735 sharesNov 20, 2026
- Market cap
- $461.2M USDAt the close on Nov 20, 2026 · price × 31.78M shares outstanding
- Traded on an average day
- $3.52M USDMedian day 170,200 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:BLSM · Home | $14.51 USD | -0.08 (-0.5%) | 270,735 | $14.34 | $15.63 | $13.90 | $14.59 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:BLSM · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $14.51 | -0.08 | -0.5% | $14.34 | $15.63 | $13.90 | 270,735 | |
| $14.59 | -0.54 | -3.6% | $15.17 | $16.75 | $14.34 | 280,171 | |
| $15.13 | +1.48 | +10.8% | $13.69 | $15.37 | $13.09 | 390,259 | |
| $13.65 | -0.37 | -2.6% | $14.00 | $14.00 | $13.26 | 98,608 | |
| $14.02 | -0.82 | -5.5% | $15.23 | $15.68 | $13.40 | 222,586 | |
| $14.84 | -1.28 | -7.9% | $16.08 | $16.08 | $14.51 | 256,382 | |
| $16.12 | +1.88 | +13.2% | $14.48 | $16.19 | $14.48 | 203,681 | |
| $14.24 | -0.22 | -1.5% | $13.74 | $14.56 | $12.97 | 175,885 | |
| $14.46 | +0.96 | +7.1% | $13.69 | $15.53 | $13.69 | 213,183 | |
| $13.50 | +1.15 | +9.3% | $12.29 | $14.09 | $12.14 | 174,332 | |
| $12.35 | -0.03 | -0.2% | $12.14 | $13.03 | $11.02 | 351,538 | |
| $12.38 | -0.03 | -0.2% | $12.45 | $13.00 | $11.24 | 297,390 | |
| $12.41 | -0.01 | -0.1% | $12.38 | $12.78 | $12.28 | 158,454 | |
| $12.42 | -1.33 | -9.7% | $13.80 | $14.23 | $12.28 | 140,741 | |
| $13.75 | -1.46 | -9.6% | $16.40 | $16.40 | $13.51 | 155,794 | |
| $15.21 | -1.25 | -7.6% | $17.00 | $17.53 | $14.90 | 98,955 | |
| $16.46 | +0.705 | +4.5% | $15.83 | $16.63 | $15.67 | 73,512 | |
| $15.76 | -0.635 | -3.9% | $16.34 | $16.94 | $15.61 | 74,206 | |
| $16.39 | +1.76 | +12.0% | $14.53 | $16.82 | $14.53 | 204,367 | |
| $14.63 | -1.18 | -7.5% | $15.82 | $15.82 | $14.42 | 84,346 | |
| $15.81 | +0.21 | +1.3% | $15.47 | $16.71 | $15.47 | 97,971 | |
| $15.60 | +1.20 | +8.3% | $14.54 | $15.68 | $14.47 | 76,269 | |
| $14.40 | +0.24 | +1.7% | $14.09 | $15.05 | $14.09 | 74,924 | |
| $14.16 | +0.22 | +1.6% | $14.10 | $14.25 | $12.93 | 189,368 | |
| $13.94 | -1.04 | -6.9% | $14.79 | $14.79 | $13.31 | 293,100 | |
| $14.98 | -0.28 | -1.8% | $15.17 | $15.53 | $14.70 | 176,500 | |
| $15.26 | -0.22 | -1.4% | $15.39 | $15.84 | $14.77 | 170,200 | |
| $15.48 | -1.79 | -10.4% | $17.25 | $17.91 | $15.35 | 118,600 | |
| $17.27 | -0.21 | -1.2% | $17.40 | $18.22 | $16.93 | 91,100 | |
| $17.48 | +0.60 | +3.6% | $16.80 | $17.77 | $16.68 | 131,800 | |
| $16.88 | +0.27 | +1.6% | $16.52 | $17.28 | $16.18 | 165,200 | |
| $16.61 | -0.68 | -3.9% | $17.17 | $17.67 | $16.12 | 253,800 | |
| $17.29 | -2.65 | -13.3% | $20.06 | $20.06 | $17.06 | 247,400 | |
| $19.94 | +0.25 | +1.3% | $19.72 | $20.11 | $19.06 | 201,500 | |
| $19.69 | +1.10 | +5.9% | $18.33 | $19.86 | $18.27 | 169,300 | |
| $18.59 | -0.05 | -0.3% | $18.49 | $19.74 | $18.46 | 152,600 | |
| $18.64 | -2.73 | -12.8% | $21.24 | $21.24 | $18.41 | 362,200 | |
| $21.37 | +0.03 | +0.1% | $21.17 | $22.20 | $20.70 | 228,500 | |
| $21.34 | +1.59 | +8.1% | $19.51 | $21.55 | $19.01 | 146,400 | |
| $19.75 | -0.72 | -3.5% | $20.46 | $21.03 | $19.33 | 203,100 | |
| $20.47 | -1.87 | -8.4% | $22.42 | $22.63 | $20.21 | 263,500 | |
| $22.34 | -2.91 | -11.5% | $25.30 | $25.81 | $21.88 | 219,400 | |
| $25.25 | -1.55 | -5.8% | $26.37 | $27.31 | $25.03 | 246,900 | |
| $26.80 | +1.06 | +4.1% | $26.09 | $27.99 | $25.12 | 292,200 | |
| $25.74 | -1.08 | -4.0% | $26.80 | $27.55 | $25.41 | 715,100 | |
| $26.82 | +0.57 | +2.2% | $26.49 | $27.80 | $25.61 | 247,600 | |
| $26.25 | +4.08 | +18.4% | $22.34 | $27.11 | $22.01 | 319,800 | |
| $22.17 | +0.43 | +2.0% | $22.50 | $23.38 | $21.71 | 148,800 | |
| $21.74 | +0.88 | +4.2% | $20.90 | $22.08 | $20.45 | 254,300 | |
| $20.86 | -0.65 | -3.0% | $21.55 | $21.90 | $20.75 | 148,900 | |
| $21.51 | -0.49 | -2.2% | $22.00 | $22.39 | $20.68 | 158,900 | |
| $22.00 | -0.93 | -4.1% | $23.00 | $23.29 | $21.82 | 136,300 | |
| $22.93 | +0.92 | +4.2% | $22.05 | $23.37 | $22.00 | 229,200 | |
| $22.01 | +1.99 | +9.9% | $20.00 | $22.16 | $19.36 | 168,700 | |
| $20.02 | +0.64 | +3.3% | $20.31 | $20.59 | $19.39 | 97,300 | |
| $19.38 | +0.39 | +2.1% | $19.10 | $19.91 | $18.84 | 109,700 | |
| $18.99 | +0.69 | +3.8% | $18.60 | $19.93 | $17.98 | 141,200 | |
| $18.30 | -1.26 | -6.4% | $19.57 | $19.57 | $17.59 | 101,600 | |
| $19.56 | -0.24 | -1.2% | $19.82 | $20.61 | $19.44 | 163,600 | |
| $19.80 | +1.34 | +7.3% | $18.25 | $19.84 | $18.25 | 102,400 | |
| $18.46 | +0.04 | +0.2% | $18.58 | $18.63 | $17.96 | 55,700 | |
| $18.42 | +2.39 | +14.9% | $16.10 | $18.80 | $16.10 | 193,500 | |
| $16.03 | -0.35 | -2.1% | $16.38 | $16.50 | $15.94 | 156,000 | |
| $16.38 | +0.58 | +3.7% | $16.00 | $16.50 | $15.75 | 111,400 | |
| $15.80 | -0.37 | -2.3% | $16.21 | $16.27 | $15.60 | 212,000 |
- Ticker
- NASDAQ:BLSM
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
BlossomHill Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Latest deck · Nov 20, 2026
AACR Symposium (November 2026)
Conference · 13 slides
Latest news
BlossomHill Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Nov 12, 2026
Closed $14.02 (-5.5%) on Nov 13, 2026
BlossomHill Therapeutics Announces Outcome from the End-of-Phase 1 Meeting with the FDA and Pivotal Phase 2 Trial Design for OMNI-EGFR™ Inhibitor, BH-30643, in EGFR C797S-Positive NSCLC
Nov 9, 2026
Closed $14.46 (+7.1%) on Nov 9, 2026
BlossomHill Therapeutics Announces Upcoming Presentation for BH-30236, an Oral Macrocyclic CLK Inhibitor, at the 68th American Society of Hematology (ASH) Annual Meeting
Nov 4, 2026
Closed $12.38 (-0.2%) on Nov 4, 2026
BlossomHill Therapeutics to Present at Guggenheim’s 3rd Annual Healthcare Innovations Conference
Nov 3, 2026
Closed $12.41 (-0.1%) on Nov 3, 2026
BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer
Oct 22, 2026
Closed $15.81 (+1.3%) on Oct 22, 2026
BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
Sep 18, 2026
Closed $25.74 (-4.0%) on Sep 18, 2026
BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference
Sep 3, 2026
Closed $20.02 (+3.3%) on Sep 3, 2026
BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer
Sep 1, 2026
Closed $18.99 (+3.8%) on Sep 1, 2026
BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC
Aug 19, 2026
Closed $16.17 (+0.4%) on Aug 19, 2026
BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering
Aug 6, 2026
Closed $16.00 (0.0%) on Aug 7, 2026
BlossomHill Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 11 in the last 12 months · 11 in all · newest Nov 12, 2026 · oldest 2026
- Decks
- 6 decks · latest Nov 20, 2026
Where BlossomHill Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:BLSM · Home listing · This page | NASDAQ | United States | USD |
| BOATS:BLSM | BOATS | United States | USD |
Valuation
Price/book 2.2× against a median of 2.5×: 5th lowest of 11 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $259.4M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.2×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.1×
- Beta vs S&P 500
- Under 6 months of closes
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| BlossomHill Therapeutics, Inc. · NASDAQ:BLSM | US$461.2M | US$259.4M | n/a | n/a | n/a | 2.2× | n/a | 0.1× | n/a |
| Sana Biotechnology, Inc. · NASDAQ:SANA | US$476.4M | US$408.5M | n/a | n/a | n/a | 2.6× | n/a | 0.3× | 2.29 |
| Regenxbio Inc. · NASDAQ:RGNX | US$473.4M | US$289.0M | n/a | 1.9× | n/a | 3.2× | −113.9% | 0.5× | 1.60 |
| Monopar Therapeutics Inc. · NASDAQ:MNPR | US$467.6M | US$362.8M | n/a | n/a | n/a | 3.7× | n/a | 0.0× | 1.18 |
| Neurogene Inc. · NASDAQ:NGNE | US$458.5M | US$106.4M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | 1.47 |
| Assembly Biosciences, Inc. · NASDAQ:ASMB | US$454.4M | US$142.3M | n/a | 2.1× | n/a | 1.5× | −16.6% | 0.0× | 1.00 |
| Shattuck Labs, Inc. · NASDAQ:STTK | US$454.2M | US$260.4M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 1.10 |
| G2GBIO, Inc. · KRX:456160 | US$451.8M | US$290.8M | n/a | 176× | n/a | 4.3× | −793.7% | 0.0× | n/a |
| DiaMedica Therapeutics Inc. · NASDAQ:DMAC | US$445.1M | US$410.4M | n/a | n/a | n/a | 15.5× | n/a | 0.0× | 1.67 |
| CytomX Therapeutics, Inc. · NASDAQ:CTMX | US$442.5M | US$98.96M | n/a | 7.0× | n/a | 1.6× | −609.0% | 0.0× | 1.21 |
| Capricor Therapeutics, Inc. · NASDAQ:CAPR | US$441.3M | US$335.9M | n/a | n/a | n/a | 2.1× | n/a | 0.4× | 0.94 |
| Median of the others | US$454.3M | US$289.9M | 4.6× | 2.5× | −361.4% | 0.0× | 1.21 |
Forecasts
4 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 35.40 USD · Analysts' mean
- EPS, year to Dec 2026
- -5.09 · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| J. Jean Cui | Scientific Founder, President and CEO |
| Jason Keyes | Executive Vice President and Chief Financial Officer |
| Vincent Liptak | Executive Vice President and General Counsel |
| Antonio Garrido-Montalban | Senior Vice President, Drug Substance |
| Ashley Preston | Senior Vice President, Head of Regulatory Affairs and Quality Assurance |
| Diane Wang | Senior Vice President, Clinical Pharmacology and Preclinical Development |
| Eugene Y. Rui | Senior Vice President, Chemistry |
| Geoff Oxnard | Executive Vice President and Chief Medical Officer |
| Jihao Zhou | Senior Vice President, Biometrics |
| Jill Stuart Smith | Senior Vice President, Clinical Operations and Project Management |
| Z. Jesse Shao | Senior Vice President, CMC |
| Zachary F. Zimmerman | Senior Vice President, Clinical Development |
| Y. Peter Li | Cofounder and Executive Chairman |
Board
| Director | Role |
|---|---|
| Y. Peter Li | Cofounder and Executive Chairman |
| Bihua Chen | Board Member |
| Carl L. Gordon | Board Member |
| J. Jean Cui | Scientific Founder, President and CEO |
| John Schmid | Board Member |
| Sheila Gujrathi | Board Member |
| Sundeep Agrawal | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 | −13.0% |
| Q2 2026 | Sep 18, 2026 · Before open | −4.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| AACR Symposium (November 2026) | Conference | 13 slides | Nov 20, 2026 |
| WCLC 2026 | Conference | 8 slides | Nov 20, 2026 |
| WCLC 2026 | Conference | 8 slides | Sep 14, 2026 |
| ASCO 2026 | Conference | 11 slides | Sep 9, 2026 |
| Investor Presentation (September 2026) | Investor deck | 37 slides | September 2026 |
| J.P. Morgan 2026 Healthcare Conference | Conference | 25 slides | January 2026 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Closed: US$168.3M raised · US$16 a share · J.P. Morgan +4 Dealers: J.P. Morgan (lead), Leerink Partners (lead), Guggenheim Securities (lead), LifeSci Capital (co-lead), H.C. Wainwright & Co. (co-lead) | Sep 18, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$16.00 a share on Aug 6, 2026.
- Price
- US$16.00 a share
- Shares offered
- 9,375,000 shares of common stock
- Offering size
- US$150 million
- Underwriters' option
- Up to 1,406,250 more shares
- Listing
- BLSM on the Nasdaq Global Select Market
- Underwriters
- J.P. Morgan, Leerink Partners, Guggenheim Securities, LifeSci Capital, H.C. Wainwright & Co. · In the order on the cover
- Shares delivered
- On or about Aug 10, 2026
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Apr 24, 2026 |
| Filed publicly | Jul 17, 2026 |
| Amended once | Aug 3, 2026 |
| Shares registered with an exchange | Aug 4, 2026 |
| Declared effective by the SEC | Aug 6, 2026 |
| Final prospectus, with the price | Aug 7, 2026 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Aug 7, 2026 |
| EFFECT · Notice that a registration is effective | Aug 6, 2026 |
| S-1MEF · Registration of more shares for the same offering | Aug 6, 2026 |
| CERT · Exchange's certificate of listing | Aug 6, 2026 |
| 8-A12B · Registration of shares for listing on an exchange | Aug 4, 2026 |
| S-1/A · Registration statement, amended | Aug 3, 2026 |
| S-1 · Registration statement | Jul 17, 2026 |
| DRS/A · Draft registration statement, amended | Jun 11, 2026 |
| DRS · Draft registration statement | Apr 24, 2026 |
Open IPO · From the cover of the final prospectus (424B4) filed Aug 7, 2026
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | 0 | 0 |
| Research and development | 56.1M | 31.8M |
| Selling, general and administrative | 7.89M | 4.59M |
| Operating income | -64.0M | -36.4M |
| Depreciation and amortization | 441.0K | 350.0K |
| EBITDA | -63.6M | -36.1M |
| Income before tax | -60.6M | -30.7M |
| Net income | -60.6M | -30.7M |
| Earnings per share, basic | -2.08 | -1.06 |
Balance sheet
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash and equivalents | 136.7M | 100.1M |
| Current assets | 138.8M | 104.2M |
| Total assets | 163.0M | 106.8M |
| Accounts payable | 2.31M | 849.0K |
| Current liabilities | 15.5M | 6.77M |
| Total debt | 22.4M | 525.0K |
| Total liabilities | 294.7M | 179.7M |
| Shareholders' equity | -131.7M | -72.9M |
| Shares outstanding | 29.1M | 29.1M |
Cash flow
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash from operations | -46.9M | -31.4M |
| Capital spending | -1.07M | -92.0K |
| Free cash flow | -48.0M | -31.5M |
| Cash from investing | -1.07M | -92.0K |
| Cash from financing | 84.5M | 17.6M |
| Change in cash | 36.5M | -13.9M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | Sep 18, 2026 | Quarterly report | SEC |
| 8-K · Current report | Sep 18, 2026 | Results | SEC |
| 8-K · Current report | Sep 15, 2026 | Current report | SEC |
| SCHEDULE 13D · Big-stake notice | Aug 18, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 17, 2026 | Big-stake notice | SEC |
All 49 filings
Cap table
Built by 6ix from BlossomHill Therapeutics, Inc.’s releases · as of Sep 30, 2026
- Common shares
- 31,784,909
- Fully diluted
- 31,784,909
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 31,784,909 | Sep 16, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Sep 16, 2026 | 31,784,909 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| John Schmid Other companies: First Tracks Biotherapeutics, Inc. (Director · Since at least Apr 1, 2026); Helix Acquisition Corp. III (Director · Since at least Jan 22, 2026); Design Therapeutics, Inc. (Director · Since at least Mar 25, 2021); AnaptysBio, Inc. (Director · Since at least Feb 2, 2018); BridgeBio Oncology Therapeutics, Inc. (Director · Feb 8, 2024 – Feb 8, 2024 · Past); Xeris Biopharma Holdings, Inc. (Director · Oct 5, 2021 – Aug 12, 2024 · Past); MoonLake Immunotherapeutics (Director · Oct 19, 2020 – Oct 19, 2020 · Past); Poseida Therapeutics Inc (Director · Jul 9, 2020 – Jan 8, 2025 · Past); Neos Therapeutics Inc (Director · Jul 2, 2018 – Mar 19, 2021 · Past) | Director · Since at least Aug 6, 2026 |
| Bihua Chen Other companies: Helix Acquisition Corp. III (Chairperson and CEO, Director · Since at least Jan 22, 2026); BridgeBio Oncology Therapeutics, Inc. (Director · Since at least Aug 11, 2025); Biomea Fusion, Inc. (Director · Since at least Jun 11, 2025) | Director · Since at least Aug 6, 2026 |
| Jason Keyes Other companies: Actuate Therapeutics, Inc. (Director · Since at least Aug 12, 2024); Sesen Bio Inc (Director · May 3, 2021 – Jun 22, 2022 · Past); Equillium, Inc. (Chief Financial Officer · Dec 10, 2020 – Feb 14, 2025 · Past) | Chief Financial Officer · Since at least Aug 6, 2026 |
| Carl L. Gordon Other companies: ADARx Pharmaceuticals, Inc. (Director · Since at least Sep 28, 2026); Electra Therapeutics, Inc. (Director · Since at least Sep 21, 2026) | Director · Since at least Aug 10, 2026 |
| Sundeep Agrawal Other companies: PAVmed Inc. (Director · Since at least Sep 10, 2024); FoxWayne Enterprises Acquisition Corp (Director · Jan 19, 2021 – Jan 19, 2021 · Past) | Board Member · Since at least Aug 6, 2026 |
| Yishan Li Other companies: Turning Point Therapeutics Inc (Director · Apr 16, 2019 – Apr 16, 2019 · Past) | Executive Chairman, Director · Since at least Aug 6, 2026 |
| Antonio Garrido-Montalban | Senior Vice President, Drug Substance · Since at least Nov 4, 2026 |
| Ashley Preston | Senior Vice President, Head of Regulatory Affairs and Quality Assurance · Since at least Nov 4, 2026 |
| Diane Wang | Senior Vice President, Clinical Pharmacology and Preclinical Development · Since at least Nov 4, 2026 |
| Eugene Y. Rui | Senior Vice President, Chemistry · Since at least Nov 4, 2026 |
All 21 people
| Person | Seat |
|---|---|
| Geoff Oxnard | Executive Vice President and Chief Medical Officer · Since at least Oct 22, 2026 |
| Geoffrey Raymond Oxnard | Chief Medical Officer · Since at least Aug 6, 2026 |
| Jihao Zhou | Senior Vice President, Biometrics · Since at least Nov 4, 2026 |
| Jill Stuart Smith | Senior Vice President, Clinical Operations and Project Management · Since at least Nov 4, 2026 |
| Jingrong Jean Cui | President and CEO, Director · Since at least Aug 6, 2026 |
| J. Jean Cui | Scientific Founder, President and CEO · Since at least Nov 4, 2026 |
| Sheila Gujrathi | Board Member · Since at least Nov 5, 2026 |
| Vincent Liptak | Executive Vice President and General Counsel · Since at least Aug 6, 2026 |
| Y. Peter Li | Cofounder and Executive Chairman · Since at least Nov 5, 2026 |
| Zachary F. Zimmerman | Senior Vice President, Clinical Development · Since at least Nov 4, 2026 |
| Z. Jesse Shao | Senior Vice President, CMC · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about BlossomHill Therapeutics, Inc.